Christopher Liu
Stock Analyst at Lucid Capital
(3.74)
# 2,027
Out of 4,453 analysts
158
Total ratings
42.7%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Maintained: Buy | $18 → $22 | $27.87 | -21.06% | 2 | Jun 22, 2026 | |
| CRDF Cardiff Oncology | Maintained: Buy | $14 → $4 | $1.21 | +230.58% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Maintained: Buy | $25 | $1.68 | +1,388.10% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $24.67 | +102.68% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $5 | $1.96 | +155.10% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $6.45 | +117.05% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $2.36 | +154.24% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye | Initiated Coverage: Buy | $11 | $10.16 | +8.27% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $17.05 | +193.26% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.87 | +328.04% | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $12.49 | +60.13% | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $4.12 | +118.45% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.90 | +244.83% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.60 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 → $37 | $53.23 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $36 | $22.46 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $3.00 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $36.29 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $38.01 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $17.83 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $69 | $123.53 | n/a | 7 | Jan 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $4.40 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $8.03 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $21.66 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $13.23 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $33.62 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $5.85 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.37 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.41 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $9.68 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.05 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0015 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Jun 22, 2026
Maintained: Buy
Price Target: $18 → $22
Current: $27.87
Upside: -21.06%
Cardiff Oncology
Jun 5, 2026
Maintained: Buy
Price Target: $14 → $4
Current: $1.21
Upside: +230.58%
NextCure
Jun 2, 2026
Maintained: Buy
Price Target: $25
Current: $1.68
Upside: +1,388.10%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $24.67
Upside: +102.68%
Actuate Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $1.96
Upside: +155.10%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $6.45
Upside: +117.05%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $2.36
Upside: +154.24%
Adlai Nortye
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $10.16
Upside: +8.27%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $17.05
Upside: +193.26%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.87
Upside: +328.04%
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $12.49
Upside: +60.13%
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $4.12
Upside: +118.45%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.90
Upside: +244.83%
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.60
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $19 → $37
Current: $53.23
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $22.46
Upside: n/a
Jan 27, 2025
Maintained: Buy
Price Target: $20
Current: $3.00
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $36.29
Upside: n/a
Feb 20, 2024
Maintained: Buy
Price Target: n/a
Current: $38.01
Upside: n/a
Feb 13, 2024
Maintained: Buy
Price Target: $18
Current: $17.83
Upside: n/a
Jan 8, 2024
Maintained: Hold
Price Target: $69
Current: $123.53
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $4.40
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $8.03
Upside: n/a
Nov 9, 2023
Maintained: Hold
Price Target: $5
Current: $21.66
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $13.23
Upside: n/a
Aug 2, 2018
Rated: Hold
Price Target: n/a
Current: $33.62
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $5.85
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $24.37
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.41
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $9.68
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $1.05
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.0015
Upside: n/a